罗欣药业：预计2025年亏损2.5亿元至3.4亿元，经营状况呈现积极改善态势

Core Viewpoint - The company, 罗欣药业, expects a net profit attributable to shareholders of approximately -340 million to -250 million yuan for the fiscal year 2025, compared to a loss of 965 million yuan in the same period last year [1] Financial Performance - The primary reason for the performance change is the company's strategic focus on the pharmaceutical industrial sector, particularly in the digestive system field, driven by the rapid growth of its core innovative drug, 替戈拉生片 (brand name: 泰欣赞) [1] - The company still anticipates a loss for 2025 due to ongoing underperformance of 上药罗欣 and confirmed fair value losses on related financial liabilities, which are classified as non-recurring gains and losses [1] Business Strategy - The company has initiated procedures to dispose of the loss-making businesses related to 乐康制药 and 罗欣安若维他, but the operational losses prior to the completion of these sales continue to impact the current period's performance [1] - The impact of these losses is expected to decrease once the disposals are finalized [1]